TY - JOUR
T1 - Oral methotrexate for recurrent brain tumors in children
T2 - A pediatric oncology group study
AU - Mulne, Arlynn F.
AU - Ducore, Jonathan M.
AU - Elterman, Roy D.
AU - Friedman, Henry S.
AU - Krischer, Jeffrey P.
AU - Kun, Larry E.
AU - Shuster, Jonathan J.
AU - Kadota, Richard P.
PY - 2000
Y1 - 2000
N2 - Purpose: Children with recurrent or progressive central nervous system (CNS) tumors have an unfavorable prognosis. Based on Pediatric Oncology Group (POG) institutional pilot data, low-dose oral methotrexate (MTX) was studied. Methods: Eight dosages of MTX 7.5 mg/m2 every 6 hours were administered on a weekly schedule for as long as 18 months. Patients in six different brain tumor strata were accrued. Results: The response rates (complete or partial responses) were as follows: astrocytoma 2 of 10, malignant glioma 1 of 19, medulloblastoma 0 of 18, brainstem tumor 0 of 12, ependymoma 1 of 7, and miscellaneous histologic types 0 of 12. The main toxicities, mucositis, myelosuppression, and hepatic transaminase elevation were considered tolerable. Conclusion: Low-dose oral MTX showed no significant activity against malignant glioma, medulloblastoma, brainstem tumors, and miscellaneous histologic types. Indeterminate but low response rates were observed in children with astrocytoma and ependymoma. This regimen will not be recommended for front-line therapy.
AB - Purpose: Children with recurrent or progressive central nervous system (CNS) tumors have an unfavorable prognosis. Based on Pediatric Oncology Group (POG) institutional pilot data, low-dose oral methotrexate (MTX) was studied. Methods: Eight dosages of MTX 7.5 mg/m2 every 6 hours were administered on a weekly schedule for as long as 18 months. Patients in six different brain tumor strata were accrued. Results: The response rates (complete or partial responses) were as follows: astrocytoma 2 of 10, malignant glioma 1 of 19, medulloblastoma 0 of 18, brainstem tumor 0 of 12, ependymoma 1 of 7, and miscellaneous histologic types 0 of 12. The main toxicities, mucositis, myelosuppression, and hepatic transaminase elevation were considered tolerable. Conclusion: Low-dose oral MTX showed no significant activity against malignant glioma, medulloblastoma, brainstem tumors, and miscellaneous histologic types. Indeterminate but low response rates were observed in children with astrocytoma and ependymoma. This regimen will not be recommended for front-line therapy.
KW - Brain tumor
KW - Methotrexate
KW - Phase II study
UR - http://www.scopus.com/inward/record.url?scp=0034456852&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034456852&partnerID=8YFLogxK
U2 - 10.1097/00043426-200001000-00008
DO - 10.1097/00043426-200001000-00008
M3 - Article
C2 - 10695820
AN - SCOPUS:0034456852
SN - 0192-8562
VL - 22
SP - 41
EP - 44
JO - American Journal of Pediatric Hematology/Oncology
JF - American Journal of Pediatric Hematology/Oncology
IS - 1
ER -